• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 23
  • 21
  • 1
  • Tagged with
  • 24
  • 24
  • 18
  • 18
  • 11
  • 11
  • 11
  • 10
  • 9
  • 8
  • 7
  • 7
  • 6
  • 6
  • 5
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
21

Investigations of the anti-hypertensive and anti-atherosclerotic properties of danshen-gegen formula.

January 2010 (has links)
Ng, Chun Fai. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2010. / Includes bibliographical references (leaves 134-150). / Abstracts in English and Chinese. / Abstract --- p.i / Acknowledgements --- p.vii / Table of Contents --- p.ix / Abbreviations --- p.xii / List of Figures --- p.xv / List of Tables --- p.xviii / Chapter Chapter 1 --- Introduction --- p.1 / Chapter 1.1 --- "Introduction to Cardiovascular Disease, Hypertension and Atherosclerosis" --- p.1 / Chapter 1.1.1 --- Cardiovascular Disease --- p.1 / Chapter 1.1.2 --- Hypertension --- p.2 / Chapter 1.1.2.1 --- Background --- p.2 / Chapter 1.1.2.2 --- Causes of Hypertension --- p.3 / Chapter 1.1.2.3 --- Current Western Management and Medication --- p.6 / Chapter 1.1.3 --- Atherosclerosis --- p.9 / Chapter 1.1.3.1 --- Background --- p.9 / Chapter 1.1.3.2 --- Pathogenesis of Atherosclerosis --- p.10 / Chapter 1.1.3.3 --- Current Western Treatment and Medication --- p.12 / Chapter 1.2 --- Selection and Introduction of Current Chinese Medicine Formula --- p.16 / Chapter 1.2.1 --- Cardiac Syndrome in Traditional Chinese Medicine --- p.16 / Chapter 1.2.2 --- Traditional Chinese Medicine as an Complementary or Alternative Medicine --- p.17 / Chapter 1.2.3 --- Selection of TCM Formula from Pharmacopoeia --- p.18 / Chapter 1.2.3.1 --- Compound Formula --- p.18 / Chapter 1.2.4 --- Introduction to Constitutional Herbal Medicine --- p.19 / Chapter 1.2.4.1 --- Danshen (Radix Salviae miltiorrhizae) --- p.19 / Chapter 1.2.4.2 --- Gegen (Radix Puerariae lobatae) --- p.20 / Chapter 1.2.4.3 --- Yanhusuo (Rhizoma Corydalis) --- p.21 / Chapter 1.2.4.4 --- Composition of the Final Formula Used in the Present Study --- p.21 / Chapter 1.2.5 --- Previous work on Danshen-Gegen Formula and its limitations --- p.22 / Chapter 1.3 --- Objectives of the Present Study --- p.25 / Chapter 1.3.1 --- Research Plan --- p.26 / Chapter Chapter 2 --- Experimental Design and General Methodology --- p.27 / Chapter 2.1 --- Source and Authentication of Raw Herbs --- p.27 / Chapter 2.2 --- Materials --- p.29 / Chapter 2.3 --- Ethical Approval --- p.31 / Chapter 2.4. --- General Methods --- p.32 / Chapter 2.4.1 --- Blood Pressure Measurement --- p.32 / Chapter 2.4.2 --- Blood Profile Measurement --- p.33 / Chapter 2.4.3 --- Vascular Reactivity Studies --- p.36 / Chapter 2.5 --- Statistical Analysis --- p.38 / Chapter Chapter 3 --- Anti-hypertensive Studies of Danshen-Gegen Formula on Rat --- p.39 / Chapter 3.1 --- Introduction --- p.39 / Chapter 3.1.1 --- In vivo Anti-Hypertensive Studies --- p.39 / Chapter 3.1.1.1 --- Spontaneously Hypertensive Rat (SHR) --- p.40 / Chapter 3.1.1.2 --- Tail-cuff Blood Pressure Measurement --- p.41 / Chapter 3.1.2 --- Detailed Underlying Mechanistic Studies --- p.42 / Chapter 3.1.2.1 --- Nitric Oxide-mediated Vasodilation --- p.42 / Chapter 3.1.2.2 --- Prostacyclin-mediated Vasodilation --- p.43 / Chapter 3.1.2.3 --- Hyperpolarization-mediated Vasodilation --- p.43 / Chapter 3.1.2.4 --- Endothelium-dependent/-independent Vasodilation --- p.46 / Chapter 3.1.3 --- Long Term Underlying Mechanistic Studies --- p.48 / Chapter 3.2 --- Methods --- p.49 / Chapter 3.2.1 --- In vivo Anti-Hypertensive Studies --- p.49 / Chapter 3.2.2 --- Detailed Underlying Mechanistic Studies --- p.51 / Chapter 3.2.3 --- Long Term Underlying Mechanistic Studies --- p.53 / Chapter 3.2.4 --- Statistical analysis --- p.56 / Chapter 3.3 --- Results --- p.58 / Chapter 3.3.1 --- In vivo Anti-Hypertensive Studies --- p.58 / Chapter 3.3.1.1 --- Preventive Effect in Hypertension --- p.58 / Chapter 3.3.1.2 --- Therapeutic Effect in Hypertension --- p.62 / Chapter 3.3.2 --- Detailed Underlying Mechanistic Studies --- p.66 / Chapter 3.3.2.1 --- DG extract-induced Vasodilation --- p.66 / Chapter 3.3.2.2 --- Endothelium-independent Vasodilation --- p.67 / Chapter 3.3.2.3 --- Nitric Oxide-mediated Vasodilation --- p.68 / Chapter 3.3.2.4 --- Prostacyclin-mediated Vasodilation --- p.69 / Chapter 3.3.2.5 --- Hyperpolarization-mediated Vasodilation --- p.70 / Chapter 3.3.3 --- Long Term Underlying Mechanistic Studies --- p.74 / Chapter 3.4 --- Discussion --- p.79 / Chapter Chapter 4 --- Anti-atherosclerosis Studies of Danshen-Gegen Formula in Rabbits --- p.89 / Chapter 4.1 --- Introduction --- p.89 / Chapter 4.1.1 --- Intima-Media Thickening --- p.89 / Chapter 4.1.2 --- Effect of High Cholesterol Diet in Rabbit --- p.90 / Chapter 4.1.3 --- Thiobarbituric Acid Reactive Substances --- p.91 / Chapter 4.2 --- Methods --- p.93 / Chapter 4.2.1 --- Pilot Study for Establishment of Experimental Protocol --- p.93 / Chapter 4.2.2 --- Effect of DG extract on Intima-media Thickening --- p.97 / Chapter 4.2.3 --- Statistical analysis --- p.99 / Chapter 4.3 --- Result --- p.100 / Chapter 4.3.1 --- Study of the Anti-atherosclerosis Effect of DG extract - First Run --- p.100 / Chapter 4.3.2 --- Study of the Anti-atherosclerosis Effect of DG extract - Second Run --- p.108 / Chapter 4.4 --- Discussion --- p.117 / Chapter Chapter 5 --- General Discussion and Conclusion --- p.122 / Chapter 5.1 --- Significance of the Study --- p.122 / Chapter 5.2 --- Limitations and Future work --- p.127 / Chapter 5.3 --- Clinical Implication of the Use of the DG Preparations for Patients with CVD --- p.132 / References --- p.134
22

Effects of Danshen and its active components on rat CYP2E1 expression and metabolism of model CYP2E1 probe substrate.

January 2009 (has links)
Cheung, Ching Mei. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2009. / Includes bibliographical references (leaves 151-162). / Abstracts in English and Chinese. / ABSTRACT --- p.I / 論文摘要 --- p.IV / ACKNOWLEDGEMENT --- p.VI / TABLE OF CONTENTS --- p.VII / ABBREVIATIONS --- p.X / Chapter Chapter 1 --- p.1 / GENERAL INTRODUCTION --- p.1 / Chapter 1.1 --- DANSHEN --- p.1 / Chapter 1.1.1 --- LIPID-SOLUBLE COMPOUNDS EXTRACTED FROM DANSHEN --- p.2 / Chapter 1.1.1.1 --- TANSHINONE I --- p.2 / Chapter 1.1.1.2 --- TANSHINONE IIA --- p.3 / Chapter 1.1.1.3 --- CRYPTOTANSHINONE --- p.3 / Chapter 1.1.1.4 --- DIHYDROTANSHINONE --- p.4 / Chapter 1.1.2 --- WATER-SOLUBLE COMPOUNDS EXTRACTED FROM DANSHEN --- p.4 / Chapter 1.1.2.1 --- DANSHENSU --- p.4 / Chapter 1.1.2.2 --- SALVIANOLIC ACID B --- p.5 / Chapter 1.2 --- DRUG-DRUG INTERACTIONS --- p.5 / Chapter 1.2.1 --- PROBLEMS ASSOCIATED WITH HERBAL ADMINISTRATION --- p.5 / Chapter 1.2.2 --- HERB-DRUG INTERACTIONS --- p.7 / Chapter 1.2.2.1 --- ST. JOHŃةS WORT-DRUG INTERACTIONS --- p.8 / Chapter 1.2.2.2 --- WARFARIN-HERB INTERACTIONS --- p.9 / Chapter 1.2.2.3 --- DANSHEN-WARFARIN INTERACTIONS --- p.10 / Chapter 1.2.2.4 --- DANSHEN-DRUG INTERACTIONS --- p.11 / Chapter 1.3 --- CYTOCHROME P450 ENZYMES (CYP) --- p.12 / Chapter 1.3.1 --- CYTOCHROME P4502E1 --- p.13 / Chapter 1.4 --- AIMS OF STUDY --- p.17 / Chapter Chapter 2 --- p.21 / EFFECTS OF DANSHEN AND SOME IF ITS ACTIVE COMPONENTS ON CHLORZOXAZONE METABOLISM IN RAT AND HUMAN LIVER MICROSOMES IN VITRO --- p.21 / Chapter 2.1 --- INTRODUCTION --- p.21 / Chapter 2.2 --- MATERIALS AND METHODS --- p.23 / Chapter 2.2.1 --- CHEMICALS AND REAGENTS --- p.23 / Chapter 2.2.2 --- PREPARATION OF AQUEOUS FRACTION OF DANSHEN --- p.23 / Chapter 2.2.3 --- PREPARATION OF ETHANOLIC FRACTION OF DANSHEN --- p.23 / Chapter 2.2.4 --- ANIMALS --- p.24 / Chapter 2.2.5 --- PREPARATION OF RAT LIVER MICROSOMES --- p.25 / Chapter 2.2.6 --- POOLED HUMAN LIVER MICROSOMES --- p.25 / Chapter 2.2.7 --- PROTEIN ASSAY --- p.25 / Chapter 2.2.8 --- MICROSOMAL INCUBATION --- p.26 / Chapter 2.2.8.1 --- RAT LIVER MICROSOMES --- p.26 / Chapter 2.2.8.2 --- HUMAN LIVER MICROSOMES --- p.26 / Chapter 2.2.9 --- INHIBITION KINETICS STUDIES --- p.27 / Chapter 2.2.9.1 --- RAT LIVER MICROSOMES --- p.27 / Chapter 2.2.9.2 --- HUMAN LIVER MICROSOMES --- p.27 / Chapter 2.2.10 --- HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) ANALYSIS --- p.28 / Chapter 2.2.11 --- DATA ANALYSIS --- p.28 / Chapter 2.3 --- RESULTS --- p.31 / Chapter 2.3.1 --- EFFECT OF DANSHEN AND TANSHINONES ON RAT CYP2E1 ACTIVITY IN VITRO / Chapter 2.3.1.1 --- SUMMARY --- p.57 / Chapter 2.3.2 --- EFFECT OF DANSHEN AND TANSHINONES ON HUMAN CYP2E1 ACTIVITYIN VITRO --- p.58 / Chapter 2.3.2.1 --- SUMMARY --- p.84 / Chapter 2.4 --- DISCUSSION --- p.85 / Chapter Chapter 3 --- p.93 / EFFECTS OF DANSHEN ON CYTOCHROME P450 PROTEIN EXPRESSION AND METABOLISM OF MODEL CYP2E1 PROBE SUBSTRATE IN THE RAT IN VIVO --- p.93 / Chapter 3.1 --- INTRODUCTION --- p.93 / Chapter 3.2 --- MATERIALS AND METHODS --- p.97 / Chapter 3.2.1 --- CHEMICALS AND REAGENTS --- p.97 / Chapter 3.2.2 --- ANIMALS --- p.97 / Chapter 3.2.3 --- EFFECTS OF DANSHEN TREATMENTS ON PHARMACOKINETICS OF CHLORZOXAZONE IN RATS IN VIVO --- p.98 / Chapter 3.2.3.1 --- "ACUTE, 3-DAY AND 14-DAY TREATMENTS WITH WHOLE DANSHEN EXTRACT" --- p.98 / Chapter 3.2.3.2 --- PLASMA EXTRACTION --- p.99 / Chapter 3.2.3.3 --- HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) ANALYSIS --- p.99 / Chapter 3.2.4 --- EFFECTS OF 3-DAY AND 14-DAY DANSHEN TREATMENTS ON CYP2E1 PROTEIN EXPRESSION --- p.101 / Chapter 3.2.4.1 --- PREPARATION OF RAT LIVER MICROSOMES FOR WESTERN BLOTTING --- p.101 / Chapter 3.2.4.2 --- PROTEIN ASSAY --- p.101 / Chapter 3.2.4.3 --- WESTERN BLOT --- p.102 / Chapter 3.2.5 --- DATA ANALYSIS --- p.103 / Chapter 3.3 --- RESULTS --- p.105 / Chapter 3.3.1 --- EFFECTS OF WHOLE DANSHEN EXTRACT ON RAT CYP2E1 ACTIVITIES IN VIVO --- p.105 / Chapter 3.3.1.1 --- EFFECTS OF ACUTE TREATMENTS OF WHOLE DANSHEN EXTRACT ON PHARMACOKINETICS OF CHLORZOXAZONE --- p.105 / Chapter 3.3.1.2 --- EFFECTS OF 3-DAY TREATMENTS OF WHOLE DANSHEN EXTRACT ON PHARMACOKINETICS OF CHLORZOXAZONE --- p.106 / Chapter 3.3.1.3 --- EFFECTS OF 14-DAY TREATMENTS OF WHOLE DANSHEN EXTRACT ON PHARMACOKINETICS OF CHLORZOXAZONE --- p.107 / Chapter 3.3.2 --- EFFECTS OF WHOLE DANSHEN EXTRACT ON RAT CYP2E1 EXPRESSION .… --- p.137 / Chapter 3.3.3 --- SUMMARY --- p.140 / Chapter 3.4 --- DISCUSSION --- p.141 / CHAPTER 4 --- p.145 / GENERAL DISCUSSION --- p.145 / REFERENCES --- p.151
23

The effect of danshen-gegen compound formula on in vitro foam cell formation and in vivo antioxidant level.

January 2007 (has links)
Wong, Wai Yin. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2007. / Includes bibliographical references (leaves 92-108). / Abstracts in English and Chinese. / Chapter Chapter 1 --- Introduction --- p.1 / Chapter 1.1 --- Atherosclerosis --- p.1 / Chapter 1.1.1 --- Pathogenesis of Atherosclerosis --- p.2 / Chapter 1.1.2 --- Atherosclerosis and Cardiovascular Disease --- p.4 / Chapter 1.2 --- Cardiovascular Disease (CVD) --- p.5 / Chapter 1.2.1 --- Term Definition --- p.5 / Chapter 1.2.2 --- Risk Factors --- p.6 / Chapter 1.2.3 --- Current Western Medications --- p.7 / Chapter 1.3 --- Reactive Oxygen Species (ROS) --- p.8 / Chapter 1.3.1 --- Impact of ROS --- p.8 / Chapter 1.3.2 --- "Superoxide Anion Radical, Hydrogen Peroxide, Hydroxyl Radical, Nitric Oxide" --- p.9 / Chapter 1.3.3 --- ROS Production by NAD(P)H Oxidases --- p.11 / Chapter 1.3.4 --- ROS Production by Mitochondria --- p.12 / Chapter 1.3.5 --- Lipid Peroxidation --- p.13 / Chapter 1.3.6 --- Other Sources of ROS --- p.15 / Chapter 1.4 --- Antioxidants --- p.16 / Chapter 1.4.1 --- Superoxide Dismutase (SOD) --- p.16 / Chapter 1.4.2 --- Catalase (CAT) --- p.17 / Chapter 1.4.3 --- Glutathinoe Peroxidase (GPx) --- p.17 / Chapter 1.4.4 --- Glutathione-S-Transferase (GST) --- p.18 / Chapter 1.4.5 --- Vitamin E --- p.18 / Chapter 1.4.6 --- Vitamin C --- p.19 / Chapter 1.5 --- Ageing --- p.19 / Chapter 1.6 --- Antioxidants and CVD --- p.21 / Chapter 1.7 --- Traditional Chinese Medicine (TCM) --- p.22 / Chapter 1.7.1 --- Danshen --- p.23 / Chapter 1.7.2 --- Gegen --- p.25 / Chapter 1.7.3 --- Danshen-Gegen Compound Formula (DG) --- p.26 / Chapter 1.8 --- Aim of Study --- p.27 / Chapter Chapter 2 --- In vitro Foam Cells Formation --- p.29 / Chapter 2.1 --- Materials and Methods --- p.29 / Chapter 2.1.1 --- Materials --- p.29 / Chapter 2.1.2 --- Methods --- p.30 / Chapter 2.1.2.1 --- Herbal Preparation by Hot Water Extraction --- p.30 / Chapter 2.1.2.2 --- Resident Peritoneal Macrophages Preparation --- p.31 / Chapter 2.1.2.3 --- "Colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl Tetrazolium Bromide (MTT) Assay" --- p.31 / Chapter 2.1.2.4 --- DG Effect on in vitro Foam Cells Formation --- p.32 / Chapter 2.2 --- Results and Discussion --- p.32 / Chapter 2.3 --- Summary --- p.39 / Chapter Chapter 3 --- In vivo Antioxidant Level --- p.40 / Chapter 3.1 --- DG Effect on in vivo Antioxidant Levels on Young-adult Wistar Rats --- p.40 / Chapter 3.1.1 --- Materials and Methods --- p.40 / Chapter 3.1.1.1 --- Herbal Preparation by Hot Water Extraction --- p.40 / Chapter 3.1.1.2 --- Assay Kits --- p.41 / Chapter 3.1.1.3 --- Antibodies for Protein Expression Determination in Organs --- p.41 / Chapter 3.1.1.4 --- Animals and Experimental Design --- p.41 / Chapter 3.1.1.5 --- Plasma Antioxidants --- p.42 / Chapter 3.1.1.6 --- Lipid Peroxidation and Protein Expression in Organs --- p.46 / Chapter 3.1.1.7 --- Statistics --- p.52 / Chapter 3.1.2 --- Results and Discussion --- p.53 / Chapter 3.2 --- DG Effect on in vivo Antioxidant Levels on Middle-aged Wistar Rats --- p.74 / Chapter 3.2.1 --- Materials and Methods --- p.75 / Chapter 3.2.2 --- Results and Discussion --- p.75 / Chapter 3.3 --- Summary --- p.87 / Chapter Chapter 4 --- Conclusion and Future Work --- p.90 / Chapter 4.1 --- Conclusion --- p.90 / Chapter 4.2 --- Future work --- p.90 / Reference --- p.92 / Related Publication --- p.109
24

Compound formula of danshen (salvia miltiorrhiza) and gegen (pueraria lobata) as adjunctive secondary preventive therapy in coronary patients.

January 2004 (has links)
Tam Wing Yin. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2004. / Includes bibliographical references (leaves 82-100). / Abstracts in English and Chinese. / English abstrac --- p.I / 中文摘要 --- p.VI / Glossary --- p.X / Chapter Chapter 1. --- Background: / Chapter 1.1. --- Coronary heart disease in Hong Kong --- p.1 / Chapter 1.2. --- Coronary heart disease and atherosclerosis --- p.2 / Chapter 1.3. --- Pathogenesis of atherosclerosis --- p.2 / Chapter 1.4. --- Risk factors for atherosclerosis --- p.5 / Chapter 1.5. --- Homocysteine --- p.6 / Chapter 1.6. --- Folate --- p.10 / Chapter 1.7. --- Vitamin B12 --- p.13 / Chapter 1.8. --- Adhesion Molecules --- p.14 / Chapter 1.9. --- Phytoestrogen --- p.17 / Chapter 1.10. --- Secondary prevention of coronary artery disease --- p.20 / Chapter Chapter 2. --- "Heart disease, Danshen and Gegen in Chinese medicine" / Chapter 2.1. --- The record of Cardiac symptoms in Chinese Medicine --- p.24 / Chapter 2.2. --- Danshen (Salvia Miltriorrhiza) --- p.25 / Chapter 2.3. --- Gegen (Radix Pueraria) --- p.28 / Chapter Chapter 3. --- Surrogate atherosclerotic markers / Chapter 3.1. --- Flow-mediated dilatation of brachial artery (FMD) --- p.31 / Chapter 3.2. --- Carotid intima media thickness (IMT) --- p.32 / Chapter Chapter 4. --- Method / Chapter 4.1. --- Rational of the study --- p.33 / Chapter 4.2. --- Clinical protocol --- p.35 / Chapter 4.3. --- Measurement of plasma homocysteine --- p.38 / Chapter 4.4. --- Measurement of folate and vitamin B12 --- p.40 / Chapter 4.5. --- Measurement of soluble cellular adhesion molecules (CAMs) --- p.41 / Chapter 4.6. --- Measurement of plasma enterolactone --- p.43 / Chapter 4.7. --- Measurement of plasma hs-C-reactive protein --- p.44 / Chapter 4.8. --- Other laboratory tests --- p.45 / Chapter 4.9. --- High resolution ultrasound imaging --- p.46 / Chapter 4.10. --- Statistical analysis --- p.49 / Chapter 4.11. --- My contribution to this joint project --- p.49 / Chapter Chapter 5. --- Results / Chapter 5.1. --- Recruitment and outcomes of subjects --- p.51 / Chapter 5.2. --- Baseline characteristics --- p.53 / Chapter 5.3. --- Medical history and treatment received in the study subjects --- p.54 / Chapter 5.4. --- Safety profiles --- p.55 / Chapter 5.5. --- Severe adverse events --- p.56 / Chapter 5.6. --- Lipid profiles --- p.57 / Chapter 5.7. --- Secondary endpoints --- p.58 / Chapter 5.8. --- Primary endopoints --- p.59 / Chapter 5.9. --- The effect of statin usage on the primary endpoints / Chapter 5.10. --- The major determinant of the change in FMD by multivariate logistic regression / Chapter 5.11. --- Progress of lipid profiles and primary endpoints in the open label phase / Chapter Chapter 6. --- Discussion / Chapter 6.1. --- Brachial FMD --- p.66 / Chapter 6.2. --- Carotid IMT --- p.69 / Chapter 6.3. --- Brachial GTN --- p.70 / Chapter 6.4. --- Lipid-lowering effect --- p.72 / Chapter 6.5. --- Phytoestrogen --- p.72 / Chapter 6.6. --- Folate --- p.73 / Chapter 6.7. --- Vitamin B12 and glucose --- p.76 / Chapter 6.8. --- Summary of possible anti-atherogenic mechanism of D&G --- p.76 / Chapter 6.9. --- Placebo effect --- p.77 / Chapter 6.10. --- Safety profile --- p.77 / Chapter 6.11. --- Limitation of the study and suggestion of solution --- p.77 / Chapter 6.12. --- Suggestions and ummary of the future work --- p.79 / Chapter Chapter 7. --- Conclusions --- p.81 / References --- p.82

Page generated in 0.0599 seconds